皮下免疫治疗注射后出现全身不良反应的伴发因素及处理

doi:10.6040/j.issn.1673-3770.0.2018.158

摘要/Abstract

摘要： 目的分析皮下免疫治疗(SCIT)注射后出现全身不良反应的伴发因素及处理方式,以便更安全实施SCIT治疗。方法回顾分析2013年1月至2017年12月在变应性疾病门诊行SCIT后出现全身变应反应的病例记录。结果 SCIT注射4597次(191例),出现全身不良反应共23次(21例),全身不良反应的发生率为0.5%,其中速发性反应17例,迟发性反应6例。出现于初始治疗阶段6例,维持治疗阶段17例。根据WAO免疫治疗指导文件进行分级,1级7例,2级15例,3级1例,4级0例,5级0例。排除伴发因素后继续原剂量注射,无不良反应发生。结论全身反应多在剂量维持期出现,饮酒、感染、食入或吸入大量变应原、热水浴、运动、疲劳、情绪应激、空腹、妊娠初期、存在其他的特异性IgE疾病等都是诱发患者对已多次注射、耐受良好的SCIT剂量出现全身不良反应的危险因素。每次注射前详细追问患者近期生活史及严格评定注射者是减少全身变应反应的重要环节。排除伴发因素后继续原剂量注射是安全的治疗方法。

关键词: 变应性鼻炎, 影响因素, 皮下免疫治疗, 全身不良反应

Abstract: Objective To analyze the factors associated with and the treatment of systemic adverse reactions after subcutaneous immunotherapy(SCIT)injections. Methods We retrospectively analyzed the records of patients with systemic anaphylaxis who presented to the Allergic Diseases Outpatient Department between January 2013 and December 2017. Results A total of 4597 SCIT injections had been administered to 191 patients, and 23 cases/instances of systemic adverse reactions were reported in 21 patients. The incidence of systemic adverse reactions was 0.5%. An immediate reaction was observed in 17 and a delayed reaction was observed in 6 cases. Systemic adverse reactions occurred during the initial treatment in 6 and during maintenance treatment in 17 cases. Based on the World Allergy Organization immunotherapy guidelines, 7 cases were classified as grade 1, 15 as grade 2, 1 as grade 3, 0 as grade 4, and 0 as grade 5. After exclusion of the associated factors, continuing to inject the original dose showed no adverse reactions. Conclusion Systemic reactions usually occur during the dose maintenance period. Alcohol intake, infections, ingestion or inhalation of a large number of allergens, hot water baths, exercise, fatigue, emotional stress, fasting, early pregnancy, and a few specific immunoglobulin E-mediated diseases are known risk factors for systemic adverse reactions in patients who receive multiple injections and tend to develop tolerance to the dose. Detailed questioning regarding the patients recent life history prior to each injection and careful assessment of the injector are important to reduce systemic allergic reactions. Continuing to inject the original dose after excluding the contributory factors is safe.

Key words: Allergic rhinitis, Subcutaneous immunotherapy, Systemic adverse reactions, Factors

中图分类号:

R765.4

王坛,武珂,李连庆,宫丽丽. 皮下免疫治疗注射后出现全身不良反应的伴发因素及处理[J]. 山东大学耳鼻喉眼学报, 2018, 32(5): 71-74.

WANG Tan, WU Ke, LI Lianqing, GONG Lili. Factors associated with systemic adverse reactions after subcutaneous immunotherapy injections and treatment options[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(5): 71-74.

参考文献 22

[1]	Knisely AJ, Lee S. Advances in subcutaneous immunotherapy[J]. Curr Opin Otolaryngol Head Neck Surg, 2014, 22(3):216-220.
[2]	邱前辉,卢川,陈建军,等. 变应性鼻炎冲击免疫治疗的安全性研究[J]. 临床耳鼻咽喉头颈外科杂志,2014,28(11):776-779, 784. QIU Qianhui, LU Chuan, CHEN Jianjun, et al. Safety of rush allergen-specific immunotherapy in allergic rhinitis patients[J]. J Clin Otorhinolaryngol Head Neck Surg, 2014, 28(11):776-779, 784.
[3]	李琳,关桂梅,朱冬冬,等. 变应性鼻炎标准化螨变应原皮下免疫治疗患者的疗效及安全性[J]. 中华耳鼻咽喉头颈外科杂志,2012,47(6):445-448. LI Lin, GUAN Guimei, ZHU Dongdong, et al. Efficacy and safety analysis with standardized mite allergen subcutaneous immunotherapy in 90 patients with allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2012, 47(6):445-448.
[4]	程雷. 变应性鼻炎的特异性免疫治疗[J]. 山东大学耳鼻喉眼学报,2011,25(5):33-35.
[5]	Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from inununotherapy(IT)and skin testing(ST)[J]. J Allergy Clin Immunol, 1987, 79(4):660-677.
[6]	Reid MJ, Lockey RF, Turkelmub PC, et al. Survey of fatalities from skin testing and immunotherapy 1985-1989[J]. J Allergy Clin Immunol, 1993, 92(1):6-15.
[7]	Bemstein DI, Wanner M, Bofish L, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001[J]. J Allergy Clin lmmunol, 2004, 113(6):1129-1136.
[8]	Epstein TG, Liss GM, Murphy-Berendts K, et al. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions[J]. J Allergy and Clinl Immunol Pract, 2014, 2(2):161-167.
[9]	Bernstein DI, Epstein T, Murphy-Berendts K, et al. Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study[J]. Ann Allergy Asthma Immunol, 2010, 104(6):530-535.
[10]	中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24. Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Head Neck Surg, 2016, 51(1): 6-24.
[11]	Alvarez CE, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61(S82):1-20.
[12]	Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy:a practice parameter third update[J]. J Allergy Clin Immunol, 2001, 127(S1):1-55.
[13]	Niggemann B, Jacobsen L, Dreborg S, et al. Five-year followup on the PAT study:specific immunotherapy and long-term prevention of asthma in children[J]. Allergy, 2006, 61(7):855-859.
[14]	Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study[J]. Clin Exp Allergy, 2001, 31(9):1392-1397.
[15]	Alvarez CE, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61(S82):1-20.
[16]	Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update[J]. J Allergy Clin Immunol, 2011, 127(S1):1-55.
[17]	Zuberbier T, Bachert C, Bousquet PJ, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma[J]. Allergy, 2010, 65(12):1525-1530.
[18]	Cox L, Larenas-Linnemann D, Lockey RF, et al. Speaking the same language: the world allergy organization subcutaneous immunotherapy systemic reaction grading system[J]. Allergy Clin Immunol, 2010, 125(3):569-574.
[19]	李孟荣,王晓宁,姜晗丹,等. 变应哮喘鼻炎患者尘螨变应原皮下免疫治疗后不良反应234例分析及处理[J]. 中国儿科杂志,2012,50(10):726-731. LI Mengrong, WANG Xiaoning, JIANG Handan, et al. Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma[J]. Chin J Pediatr, 2012, 50(10):726-731.
[20]	祝凤霞,张融,徐金梅,等. 儿童屋尘螨变应原皮下特异性免疫疗法的不良反应分析[J].实用临床医药杂志,2013,17(22):196-197.
[21]	中国变应性鼻炎研究协作组. 变应性鼻炎皮下免疫治疗专家共识2015[J]. 中国耳鼻咽喉头颈外科,2015,22(8):379-404.
[22]	Alvare-Cuesta E, Bousquet J, Canorica GW, et al. Standards for practical allergen-specific immunotherapy[J]. Allergy, 2006, 61(S82):1-20.

相关文章 15

[1]	吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28.
[2]	顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111.
[3]	秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77.
[4]	熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167.
[5]	许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[6]	刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48.
[7]	张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[8]	吕勇,冯云. 双感官障碍人群心血管疾病风险的预测模型:基于CHARLS的分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 122-128.
[9]	张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134.
[10]	刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58.
[11]	周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176.
[12]	王曼娴,郑泉,杨亮. 细菌裂解物治疗变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 141-145.
[13]	刘畅,方宏艳,刘敩,富东娜,王贺,王晶,杨景朴. 长春地区秋季变应性鼻炎蒿属花粉致敏特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 13-19.
[14]	李婷,赵冲,吴献. 鼻黏膜组织中miR-34a表达与慢性鼻窦炎患者术后复发的关系[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 20-25.
[15]	韩静静,温晓文,王雅莉,郭玉洁,李娜,孙兰. 甲状腺乳头状癌开放式手术后患者体像认知现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 37-42.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed